iA Global Asset Management Inc. Boosts Stock Holdings in Insulet Co. (NASDAQ:PODD)

iA Global Asset Management Inc. increased its position in shares of Insulet Co. (NASDAQ:PODD) by 131.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,756 shares of the medical instruments supplier’s stock after purchasing an additional 2,698 shares during the period. iA Global Asset Management Inc.’s holdings in Insulet were worth $1,242,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. purchased a new position in Insulet in the fourth quarter valued at about $36,000. SRS Capital Advisors Inc. increased its holdings in Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock valued at $49,000 after buying an additional 56 shares in the last quarter. Friedenthal Financial purchased a new position in Insulet in the fourth quarter valued at about $57,000. TD Private Client Wealth LLC increased its holdings in Insulet by 32.6% in the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after buying an additional 56 shares in the last quarter. Finally, Assetmark Inc. increased its holdings in Insulet by 1,447.1% in the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock valued at $69,000 after buying an additional 246 shares in the last quarter.

Insider Activity

In other news, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.47% of the company’s stock.

Insulet Stock Up 1.1 %

Shares of PODD opened at $268.32 on Friday. The firm has a market cap of $18.84 billion, a PE ratio of 46.34, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29. The company’s fifty day moving average is $272.04 and its two-hundred day moving average is $256.71. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $289.46. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. Analysts forecast that Insulet Co. will post 3.92 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. JPMorgan Chase & Co. increased their target price on shares of Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a report on Thursday, December 12th. Royal Bank of Canada began coverage on shares of Insulet in a research note on Thursday, March 6th. They set an “outperform” rating and a $340.00 price objective for the company. Wells Fargo & Company raised their price objective on shares of Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. StockNews.com cut shares of Insulet from a “buy” rating to a “hold” rating in a research note on Tuesday, March 4th. Finally, Raymond James reissued an “outperform” rating and set a $328.00 price objective (up from $294.00) on shares of Insulet in a research note on Friday, February 21st. Four equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $292.06.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.